🍽️ lanatoside c,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Congestive Heart Failure (CHF): Lanatoside C is used to treat congestive heart failure, a condition where the heart is unable to pump blood effectively to meet the body's needs. It works by increasing the force and efficiency of heart contractions, which helps improve cardiac output and alleviate symptoms such as shortness of breath, fatigue, and fluid retention.

  2. Atrial Fibrillation (AFib): Atrial fibrillation is a common heart rhythm disorder characterized by irregular and often rapid heartbeats. Lanatoside C can be used to control heart rate in patients with atrial fibrillation by slowing down the conduction of electrical impulses in the heart, thereby restoring a more regular heart rhythm.

  3. Supraventricular Tachycardia (SVT): Lanatoside C may also be used in the management of certain supraventricular tachycardias, which are rapid heart rhythms originating above the ventricles. By slowing down the heart rate and improving the efficiency of heart contractions, lanatoside C can help restore normal heart rhythm in some cases of SVT.

  4. Atrial Flutter: Similar to atrial fibrillation, atrial flutter is a heart rhythm disorder characterized by rapid and regular contractions of the atria. Lanatoside C may be used to control heart rate and restore normal sinus rhythm in patients with atrial flutter.

  5. Cardiogenic Shock: In some cases of severe heart failure or heart attack, cardiogenic shock may occur, which is a life-threatening condition characterized by inadequate blood flow to vital organs. Lanatoside C may be used as part of the treatment regimen to improve heart function and cardiac output in patients with cardiogenic shock.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of lanatoside c,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by lanatoside c,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Lachnospira genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Bifidobacterium genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lacrimispora genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Eggerthella genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
[Ruminococcus] torques species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bacteroides caccae species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides ovatus species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Eggerthella lenta species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of lanatoside c,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
Acne 0.1 -0.1
ADHD 0.6 0 0
Age-Related Macular Degeneration and Glaucoma 0.1 0 0
Allergic Rhinitis (Hay Fever) 0.2 0.4 -1
Allergies 0.6 0.1 5
Allergy to milk products 0.3 0.2 0.5
Alopecia (Hair Loss) 0 0
Alzheimer's disease 0.7 1.2 -0.71
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.7 0.2 2.5
Ankylosing spondylitis 0.3 0.4 -0.33
Anorexia Nervosa 0 0.4 0
Antiphospholipid syndrome (APS) 0.5 0.2 1.5
Asthma 0.1 0.1 0
Atherosclerosis 0.2 0.1 1
Atrial fibrillation 0.4 0.4 0
Autism 0.6 1.6 -1.67
Barrett esophagus cancer 0 0
benign prostatic hyperplasia 0.1 0.1
Bipolar Disorder 0.4 0.1 3
Brain Trauma 0.1 0.1 0
Cancer (General) 0.5 -0.5
Carcinoma 0.5 0.2 1.5
Celiac Disease 0.2 0.8 -3
Cerebral Palsy 0.1 0.2 -1
Chronic Fatigue Syndrome 0.7 0.5 0.4
Chronic Kidney Disease 0.3 0.3 0
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0 0.3 0
Chronic Urticaria (Hives) 0.2 0.1 1
Coagulation / Micro clot triggering bacteria 0.2 0.1 1
Colorectal Cancer 0.7 0.1 6
Constipation 0.4 0.1 3
Coronary artery disease 0.1 0.1
COVID-19 1.3 1.4 -0.08
Crohn's Disease 0.9 1.1 -0.22
cystic fibrosis 0.2 0.2 0
deep vein thrombosis 0.2 0.1 1
Depression 1.5 0.7 1.14
Dermatomyositis 0.1 -0.1
Eczema 0.1 0.2 -1
Endometriosis 0.4 0.3 0.33
Eosinophilic Esophagitis 0 0
Epilepsy 0.4 0.2 1
Fibromyalgia 0.2 0.2 0
Functional constipation / chronic idiopathic constipation 1.1 0.6 0.83
gallstone disease (gsd) 0.2 0.2 0
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.2
Generalized anxiety disorder 0.2 0.4 -1
Graves' disease 0.2 0.1 1
Halitosis 0.1 0.1
Hashimoto's thyroiditis 0.3 0.3 0
Hidradenitis Suppurativa 0.2 0.2
Histamine Issues 0.8 0.1 7
hyperglycemia 0.1 0.2 -1
Hyperlipidemia (High Blood Fats) 0.1 0 0
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 0.3 0.8 -1.67
Hypothyroidism 0.1 -0.1
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.9 -0.9
Inflammatory Bowel Disease 0.5 1 -1
Insomnia 0.1 0.3 -2
Intelligence 0 0
Intracranial aneurysms 0.2 0 0
Irritable Bowel Syndrome 0.9 0.5 0.8
Liver Cirrhosis 0.5 0.4 0.25
Long COVID 1 1.9 -0.9
Low bone mineral density 0.3 -0.3
Lung Cancer 0.2 0.1 1
Mast Cell Issues / mastitis 0.1 0.1 0
ME/CFS with IBS 0.1 -0.1
ME/CFS without IBS 0.1 0.1 0
Menopause 0.3 0.3
Metabolic Syndrome 1 1.1 -0.1
Mood Disorders 1.7 0.7 1.43
Multiple Sclerosis 0.6 0.8 -0.33
Multiple system atrophy (MSA) 0.1 0.1 0
neuropathic pain 0.5 -0.5
Neuropathy (all types) 0.1 -0.1
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 0.7 -6
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 0.9 0.3 2
obsessive-compulsive disorder 0.8 0.3 1.67
Osteoarthritis 0.1 0.1 0
Osteoporosis 0.2 0.1 1
Parkinson's Disease 0.4 0.6 -0.5
Polycystic ovary syndrome 0.2 0.2 0
Postural orthostatic tachycardia syndrome 0.1 -0.1
Premenstrual dysphoric disorder 0.1 0 0
primary biliary cholangitis 0 0
Psoriasis 0.4 0.2 1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.8 0.4 1
Rosacea 0.3 0.1 2
Schizophrenia 0.9 0.2 3.5
scoliosis 0.6 -0.6
Sjögren syndrome 0.1 0.2 -1
Sleep Apnea 0.1 0.1 0
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2 0
Stress / posttraumatic stress disorder 0.4 0.2 1
Systemic Lupus Erythematosus 0.5 0.4 0.25
Tic Disorder 0.1 0.1 0
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 0.5 0.3 0.67
Type 2 Diabetes 1 1 0
Ulcerative colitis 0.4 0.5 -0.25
Unhealthy Ageing 0.6 0.1 5

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]